Approches de gene silencing pour le traitement de la maladie de Huntington [Gene silencing approaches for the treatment of Huntington's disease].


Autoria(s): Merienne N.; Déglon N.
Data(s)

2015

Resumo

Huntington's disease is a rare neurodegenerative disease caused by a pathologic CAG expansion in the exon 1 of the huntingtin (HTT) gene. Aggregation and abnormal function of the mutant HTT (mHTT) cause motor, cognitive and psychiatric symptoms in patients, which lead to death in 15-20 years. Currently, there is no treatment for HD. Experimental approaches based on drug, cell or gene therapy are developed and reach progressively to the clinic. Among them, mHTT silencing using small non-coding nucleic acids display important physiopathological benefit in HD experimental models.

Identificador

http://serval.unil.ch/?id=serval:BIB_0E4FAB1502A7

isbn:0767-0974 (Print)

pmid:25744262

doi:10.1051/medsci/20153102012

isiid:000352503700011

Idioma(s)

fr

Fonte

Médecine Sciences : M/s, vol. 31, no. 2, pp. 159-167

Palavras-Chave #Alleles; Animals; Blood-Brain Barrier; Dependovirus/genetics; Disease Models, Animal; Gene Expression Regulation; Gene Silencing; Genetic Therapy/adverse effects; Genetic Therapy/methods; Genetic Vectors/adverse effects; Genetic Vectors/therapeutic use; Humans; Huntington Disease/genetics; Huntington Disease/therapy; Injections, Intraventricular; Lentivirus/genetics; Mice; Nerve Tissue Proteins/antagonists & inhibitors; Nerve Tissue Proteins/chemistry; Oligonucleotides, Antisense/administration & dosage; Oligonucleotides, Antisense/therapeutic use; Polymorphism, Single Nucleotide; Protein Aggregates; Protein Aggregation, Pathological/etiology; Protein Aggregation, Pathological/genetics; RNA, Messenger/antagonists & inhibitors; RNA, Small Interfering/administration & dosage; RNA, Small Interfering/therapeutic use; Trinucleotide Repeat Expansion/genetics
Tipo

info:eu-repo/semantics/review

article